Drug intelligence / Profile preview

BI 44370

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

**BI 44370** is an investigational small molecule drug developed as an oral antagonist of the calcitonin gene-related peptide (CGRP) receptor, intended for the acute treatment of migraine attacks. It was designed to provide rapid pain relief without the cardiovascular side effects associated with triptans, a commonly used class of migraine medications[2][4][5]. Clinical studies demonstrated dose-dependent efficacy in achieving pain freedom two hours after administration, with higher doses showing significant benefit over placebo and a low frequency of adverse events[2][7]. Despite promising phase II results, development was discontinued and it is not marketed for any indication[4][9].

Other names: J3.353.239CJ-3.353.239CJ 3.353.239C

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on BI 44370.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 44370.

Explore the full profile